{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-007003","form_type":"8-K","ticker":"AVR","cik":"0002011514","company_name":"Anteris Technologies Global Corp.","filed_at":"2026-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.985226+00:00","generated_at":"2026-05-15T23:14:16.554996+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Anteris reports FY2025 revenue down 29%, net loss widens to $94M; starts PARADIGM trial","bullets":["FY2025 revenue $1.9M (-29% YoY); net loss $94.1M (23% wider); cash used in ops $77.8M.","R&D expenses $69.1M focused on DurAVR THV trial preparation; SG&A $26.1M.","Initiated global PARADIGM pivotal trial for DurAVR THV; FDA IDE approval in Q4 2025.","Raised $320M in early 2026 including Medtronic investment to fund trial and commercialization.","Net tangible assets per share turned negative to ($0.01) from $1.74; all IPO proceeds fully used."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-007003","json":"https://secwatch.observer/filing/0001140361-26-007003.json","markdown":"https://secwatch.observer/filing/0001140361-26-007003.md","text":"https://secwatch.observer/filing/0001140361-26-007003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2011514/000114036126007003/0001140361-26-007003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2011514/000114036126007003/ef20066524_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:14:16.554996+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}